OMass Therapeutics Closes $310 Million Series C to Advance OMS1620 into Phase 2

OMass Therapeutics, an Oxford-based biotech developing small molecules against highly validated target ecosystems, has closed an oversubscribed $310 million (£230 million) Series C round. The funds will support development of OMS1620, a potential best-in-class MC2 (melanocortin-2) receptor antagonist, through Phase 2 studies in congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. The financing was announced on 15 October.